Camurus Annual Report for 2021 is now available at the company's website.
“2021 was a productive and successful year for Camurus where we, under challenging market conditions, continued to advance our business towards our strategic goals. Revenues grew by high double digits and the operating result continued to improve whilst we made significant investments in our pipeline of innovative medicines. We received new and extended regulatory approvals for Buvidal® for the treatment of opioid dependence and advanced key development programs towards the market”, says Fredrik Tiberg, President and CEO of Camurus.
The annual report can be found at Camurus' website: www.camurus.com.
Latest news
2018-12-07
Buvidal® Weekly and Buvidal® Monthly (CAM2038) approved in Australia as the first long-acting treatment of opioid dependence
Camurus announced today that the Australian Therapeutic Goods Administration (TGA) has approved the company’s lead p…
